AZN: Tozorakimab cut COPD exacerbations by up to 34% in Phase III, supporting 2030 growth targets
Category: Health
Share
Archive
Like
Aiming for $80bn revenue by 2030, the R&I portfolio is central to long-term growth, with tozorakimab showing up to 34% reduction in COPD exacerbations across all eosinophil levels in Phase III trials. Safety was comparable to placebo, and market expansion is underway.
Original document: AstraZeneca PLC [AZN] Slides Release — Sep. 8 2026
A note on cookies
Newshunt uses essential cookies to keep you signed in and to remember your language and country, so the site works the way you expect. With your permission, we'd also like to use analytics cookies to understand how people use Newshunt and improve it over time.
Accepting only affects analytics. To learn more, view our Privacy Policy or Terms & Conditions.
(0)Comments